A practical guide for prescribers on helping patients reduce their out-of-pocket costs for Fluticasone/Vilanterol (Breo Ellipta), including manufacturer programs, coupons, generics, and cost conversation strategies.
You prescribe Fluticasone/Vilanterol (Breo Ellipta) because it works — once-daily dosing, strong efficacy data for both asthma and COPD, and the simple Ellipta device that improves adherence. But for many of your patients, the price is a barrier they may not bring up until they've already abandoned the prescription at the pharmacy counter.
Medication non-adherence driven by cost is a well-documented problem in respiratory care. A 2024 IQVIA report estimated that nearly 30% of new respiratory prescriptions go unfilled, with cost cited as the primary reason. For a medication that relies on daily, consistent use to deliver its full benefit, that's a clinical problem as much as a financial one.
This guide equips you with practical strategies to help your patients afford Fluticasone/Vilanterol — and keep using it.
Understanding the cost landscape helps you have more informed conversations with patients.
Most commercial plans cover Breo Ellipta, typically on Tier 3 (preferred brand) or Tier 4 (non-preferred brand). Patient copays generally range from $30–$75 per fill. However, plans increasingly require:
Medicare beneficiaries face a different challenge. Breo Ellipta is covered under most Part D plans, but patients in the coverage gap ("donut hole") can face significantly higher costs. The manufacturer savings card is not valid for Medicare, Medicaid, or other government-insured patients — a point that catches many providers off guard.
For uninsured patients, the full cash price is often prohibitive. These patients benefit most from the GSK Patient Assistance Program and discount coupon cards (discussed below).
GlaxoSmithKline offers a savings card that allows eligible commercially insured patients to pay as little as $10 per prescription. Key details:
For patients with commercial insurance and high copays, this is often the single most impactful cost-reduction tool.
For patients who are uninsured or underinsured and meet income requirements (generally household income at or below 300% of the Federal Poverty Level), GSK provides Breo Ellipta at no cost.
This is an underutilized resource. If your practice treats a significant uninsured population, consider building PAP enrollment into your workflow.
For patients who don't qualify for manufacturer programs — or who use the authorized generic — third-party coupon cards can provide meaningful savings.
Many patients don't know these tools exist. A simple instruction like "Before you fill this, check GoodRx.com for a coupon — it might save you $50 or more" can make a real difference. Some practices print coupon information on handouts or include it in after-visit summaries.
Important caveat: coupon card prices do not count toward insurance deductibles. For patients working toward their deductible, paying the insurance price (even if higher) may be strategically better in the long run.
An authorized generic version of Breo Ellipta has been available since 2019. It's the same medication in the same Ellipta device, manufactured by the same company, at a lower price point ($250–$350 vs. $350–$450 for brand). Some pharmacies automatically dispense the generic unless "dispense as written" is specified.
When Fluticasone/Vilanterol is not affordable or not covered, consider therapeutic alternatives within the ICS/LABA class:
Switching from once-daily to twice-daily dosing is a trade-off. The clinical benefit of Fluticasone/Vilanterol's adherence advantage may be lost if the patient can't afford it and doesn't use it consistently. A less expensive medication taken reliably often outperforms a more expensive one taken sporadically.
For a full discussion of alternatives, see our clinical overview: Alternatives to Fluticasone/Vilanterol.
The most effective cost interventions happen before the patient reaches the pharmacy. Here are practical strategies:
A simple question — "Do you have any concerns about medication costs?" — opens the door. Many patients feel embarrassed to raise financial issues unless invited to do so. Normalizing the conversation reduces abandonment rates.
If your EHR has formulary lookup tools, use them. Prescribing a medication that's on the patient's preferred tier eliminates the most common barrier. If Breo Ellipta is non-preferred but Symbicort is preferred, that information should inform your prescribing decision — or at minimum, trigger a prior authorization.
When you know a PA is likely, submit it at the time of prescribing rather than waiting for the pharmacy rejection. Many EHR systems support electronic prior authorization (ePA). A proactive PA reduces the time the patient goes without medication.
Front desk and MA staff can be trained to provide cost resources. A simple handout with the GSK savings card URL, GoodRx instructions, and the PAP phone number can be given at checkout. Some practices designate a staff member as a "financial navigator" for medication cost issues.
Medfinder for Providers helps you and your staff locate Fluticasone/Vilanterol availability and compare pharmacy pricing. It's a practical tool for the prescribing workflow, especially when patients need help finding stock or comparing costs across pharmacies.
Consider checking whether patients actually filled their prescriptions at the 2-week follow-up. If they didn't, cost is often the reason — and that's the moment to intervene with savings options.
Since manufacturer savings cards don't apply, Medicare patients have fewer options. Strategies include:
Patients with both Medicare and Medicaid typically have low or no copays through their plan. However, formulary restrictions still apply, and step therapy requirements may need to be addressed.
These patients effectively pay cash prices until they meet their deductible. The GSK savings card is particularly valuable here. Encourage these patients to apply early in the plan year.
Cost should never be the reason a patient with asthma or COPD goes without effective maintenance therapy. As prescribers, we have more tools than ever to help patients afford Fluticasone/Vilanterol — from manufacturer programs and coupon cards to generics and therapeutic alternatives.
The key is building cost awareness into the prescribing process, not treating it as an afterthought. A two-minute conversation at the point of prescribing can prevent a $400 surprise at the pharmacy and keep your patients adherent to the therapy they need.
For additional clinical resources, explore our provider-focused articles on shortage updates for prescribers and helping patients find Fluticasone/Vilanterol in stock. And visit Medfinder for Providers to streamline your medication availability workflow.
You focus on staying healthy. We'll handle the rest.
Try Medfinder Concierge FreeMedfinder's mission is to ensure every patient gets access to the medications they need. We believe this begins with trustworthy information. Our core values guide everything we do, including the standards that shape the accuracy, transparency, and quality of our content. We’re committed to delivering information that’s evidence-based, regularly updated, and easy to understand. For more details on our editorial process, see here.
%2C%20Color%3DOriginal.png)
